Cholesterol and Alzheimer's disease - Is there a relation?

Mechanisms of Ageing and Development

Volumn 127, Issue 2, 2006, Pages 138-147

  Sjögren, Magnus ^a   Mielke, Michelle ^b   Gustafson, Deborah ^c   Zandi, Peter ^b   Skoog, Ingmar ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Amyloid; Alzheimer's disease; Amyloid precursor protein; Cholesterol; Statins

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALLELE; ALZHEIMER DISEASE; AMINO ACID SYNTHESIS; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; APOLIPOPROTEINS E; ASPARTIC ENDOPEPTIDASES; CHOLESTEROL; ENDOPEPTIDASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SENILE PLAQUES;

EID: 31644446183     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2005.09.020     Document Type: Conference Paper

References (148)

1. P. Alaupovic The role of apolipoproteins in lipid transport processes Ric. Clin. Lab. 12 1982 3 21
2. M.K. Aronson, W.L. Ooi, H. Morgenstern, A. Hafner, D. Masur, H. Crystal, W.H. Frishman, D. Fisher, and R. Katzman Women, myocardial infarction, and dementia in the very old Neurology 40 1990 1102 1106
3. K.R. Bales, T. Verina, R.C. Dodel, Y. Du, L. Altstiel, M. Bender, P. Hyslop, E.M. Johnstone, S.P. Little, D.J. Cummins, P. Piccardo, B. Ghetti, and S.M. Paul Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition Nat. Genet. 17 1997 263 264
4. U. Beffert, N. Aumont, D. Dea, S. Lussier Cacan, J. Davignon, and J. Poirier Beta-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons J. Neurochem. 70 1998 1458 1466
5. U. Beffert, N. Aumont, D. Dea, S. Lussier-Cacan, J. Davignon, and J. Poirier Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures Brain Res. Mol. Brain Res. 68 1999 181 185
6. U. Beffert, and J. Poirier Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease Ann. N. Y. Acad. Sci. 777 1996 166 174
7. U. Beffert, and J. Poirier ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation Neuroreport 9 1998 3321 3323
8. I. Bjorkhem, D. Lutjohann, U. Diczfalusy, L. Stahle, G. Ahlborg, and J. Wahren Cholesterol homeostasis in human brain: turnover of 24S- hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation J. Lipid Res. 39 1998 1594 1600
9. I. Bjorkhem, and S. Meaney Brain cholesterol: long secret life behind a barrier Arterioscler. Thromb. Vasc. Biol 2004
10. K. Blennow, and I. Skoog Genetic testing for Alzheimer's disease: how close is reality? Curr. Opin. Psychiatry 12 1999 487 493
11. R.S. Blumenthal Statins: effective antiatherosclerotic therapy Am. Heart J. 139 2000 577 583
12. S. Bodovitz, and W.L. Klein Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein J. Biol. Chem. 271 1996 4436 4440
13. M. Bonarek, P. Barberger-Gateau, L. Letenneur, V. Deschamps, A. Iron, B. Dubroca, and J.F. Dartigues Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study Neuroepidemiology 19 2000 141 148
14. V. Bonn, R.C. Cheung, B. Chen, C. Taghibiglou, S.C. Van Iderstine, and K. Adeli Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes Atherosclerosis 163 2002 59 68
15. B. Borroni, S. Archetti, C. Agosti, N. Akkawi, C. Brambilla, L. Caimi, C. Caltagirone, M. Di Luca, and A. Padovani Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer disease: from risk factors to disease modulators Neurobiol. Aging 25 2004 747 751
16. J.K. Boyles, C.D. Zoellner, L.J. Anderson, L.M. Kosik, R.E. Pitas, K.H. Weisgraber, D.Y. Hui, R.W. Mahley, P.J. Gebicke-Haerter, and M.J. Ignatius A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve J. Clin. Invest. 83 1989 1015 1031
17. R. Brookmeyer, S. Gray, and C. Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am. J. Public Health 88 1998 1337 1342
18. B.G. Brown, X.Q. Zhao, D.E. Sacco, and J.J. Albers Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease Circulation 87 1993 1781 1791
19. S.A. Brown, R. Hutchinson, J. Morrisett, E. Boerwinkle, C.E. Davis, A.M. Gotto Jr., and W. Patsch Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study Arterioscler. Thromb. 13 1993 1139 1158
20. P. Caramelli, R. Nitrini, R. Maranhao, A.C. Lourenco, M.C. Damasceno, C. Vinagre, and B. Caramelli Increased apolipoprotein B serum concentration in Alzheimer's disease Acta Neurol. Scand. 100 1999 61 63
21. K.A. Chalmers, D. Culpan, P.G. Kehoe, G.K. Wilcock, A. Hughes, and S. Love APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease Neuroreport 15 2004 95 98
22. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines, and M.A. Pericak-Vance Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 1993 921 923
23. C. Courtney, D. Farrell, R. Gray, R. Hills, L. Lynch, E. Sellwood, S. Edwards, W. Hardyman, J. Raftery, P. Crome, C. Lendon, H. Shaw, and P. Bentham Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Lancet 363 2004 2105 2115
24. M. Crisby, G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu, and J. Nilsson Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 2001 926 933
25. B. Cucchiara, and S.E. Kasner Use of statins in CNS disorders J. Neurol. Sci. 187 2001 81 89
26. K. Czyzewski, M.M. Lalowski, A. Pfeffer, and M. Barcikowska Lipid metabolism parameters in patients with Alzheimer's disease and their first degree relatives Acta Neurobiol. Exp. (Wars.) 61 2001 21 26
27. J. Davignon, and R. Laaksonen Low-density lipoprotein-independent effects of statins Curr. Opin. Lipidol. 10 1999 543 559
28. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 98 2001 8850 8855
29. P. Desai, S.T. DeKosky, and M.I. Kamboh Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease Neurosci. Lett. 328 2002 9 12
30. G.P. Eckert, C. Kirsch, and W.E. Mueller Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice Neuroreport 12 2001 883 887
31. R. Ehehalt, P. Keller, C. Haass, C. Thiele, and K. Simons Amyloidogenic processing of the Alzheimer {beta}-amyloid precursor protein depends on lipid rafts J. Cell Biol. 160 2003 113 123
32. T. Erkinjuntti, R. Sulkava, and R. Tilvis Is determination of plasma lipids useful in the differentiation of multi-infarct dementia from Alzheimer's disease? Compr. Gerontol. [A] 2 1988 1 6
33. M. Eto, K. Watanabe, N. Chonan, and K. Ishii Familial hypercholesterolemia and apolipoprotein E4 Atherosclerosis 72 1988 123 128
34. W.H. Ettinger, P.W. Wahl, L.H. Kuller, T.L. Bush, R.P. Tracy, T.A. Manolio, N.O. Borhani, N.D. Wong, D.H. O'Leary The CHS Collaborative Research Group Lipoprotein lipids in older people. Results from the Cardiovascular Health Study Circulation 86 1992 858 869
35. E.R. Frears, D.J. Stephens, C.E. Walters, H. Davies, and B.M. Austen The role of cholesterol in the biosynthesis of beta-amyloid Neuroreport 10 1999 1699 1705
36. C. Furman, C. Copin, M. Kandoussi, R. Davidson, M. Moreau, F. McTaggiart, M.J. Chapman, J.C. Fruchart, and M. Rouis Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability Atherosclerosis 174 2004 93 98
37. J.L. Galbete, T.R. Martin, E. Peressini, P. Modena, R. Bianchi, and G. Forloni Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway Biochem. J. 348 Pt 2 2000 307 313
38. F. Giubilei, R. D'Antona, R. Antonini, G.L. Lenzi, G. Ricci, and C. Fieschi Serum lipoprotein pattern variations in dementia and ischemic stroke Acta Neurol. Scand. 81 1990 84 86
39. M. Goedert Tau protein and the neurofibrillary pathology of Alzheimer's disease Trends Neurosci. 16 1993 460 465
40. M. Goedert, C.M. Wischik, R.A. Crowther, J.E. Walker, and A. Klug Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau Proc. Natl. Acad. Sci. U.S.A. 85 1988 4051 4055
41. D. Gustafson, E. Rothenberg, K. Blennow, B. Steen, and I. Skoog An 18-year follow-up of overweight and risk of Alzheimer disease Arch. Intern. Med. 163 2003 1524 1528
42. C. Haass, and D.J. Selkoe Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide Cell 75 1993 1039 1042
43. I. Hajjar, J. Schumpert, V. Hirth, D. Wieland, and G.P. Eleazer The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment J. Gerontol. A Biol. Sci. Med. Sci. 57 2002 414 418
44. H. Hartmann, A. Eckert, and W.E. Muller Apolipoprotein E and cholesterol affect neuronal calcium signalling: the possible relationship to beta-amyloid neurotoxicity Biochem. Biophys. Res. Commun. 200 1994 1185 1192
45. Heart Protection Study Collaborative Group, 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22.
46. D. Heber, B.J. Koziol, and L.C. Henson Low density lipoprotein receptor regulation and the cellular basis of atherosclerosis: implications for nutritional and pharmacologic treatment of hypercholesterolemia Am. J. Cardiol. 60 1987 4G 8G
47. P.R. Hebert, J.M. Gaziano, K.S. Chan, and C.H. Hennekens Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials JAMA 278 1997 313 321
48. O. Hernandez-Perera, D. Perez-Sala, J. Navarro-Antolin, R. Sanchez-Pascuala, G. Hernandez, C. Diaz, and S. Lamas Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J. Clin. Invest. 101 1998 2711 2719
49. O. Hernandez-Perera, D. Perez-Sala, E. Soria, and S. Lamas Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells Circ. Res. 87 2000 616 622
50. A. Hofman, A. Ott, M.M. Breteler, M.L. Bots, A.J. Slooter, F. van Harskamp, C.N. van Duijn, C. Van Broeckhoven, and D.E. Grobbee Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study Lancet 349 1997 151 154
51. D.M. Holtzman, K.R. Bales, T. Tenkova, A.M. Fagan, M. Parsadanian, L.J. Sartorius, B. Mackey, J. Olney, D. McKeel, D. Wozniak, and S.M. Paul Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 97 2000 2892 2897
52. L.S. Honig, M.X. Tang, S. Albert, R. Costa, J. Luchsinger, J. Manly, Y. Stern, and R. Mayeux Stroke and the risk of Alzheimer disease Arch. Neurol. 60 2003 1707 1712
53. D.S. Howland, S.P. Trusko, M.J. Savage, A.G. Reaume, D.M. Lang, J.D. Hirsch, N. Maeda, R. Siman, B.D. Greenberg, R.W. Scott, and D.G. Flood Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol J. Biol. Chem. 273 1998 16576 16582
54. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 9242 2000 1627 1631
55. A. Jula, J. Marniemi, R. Huupponen, A. Virtanen, M. Rastas, and T. Ronnemaa Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial JAMA 287 2002 598 605
56. H. Jurevics, and P. Morell Cholesterol for synthesis of myelin is made locally, not imported into brain J. Neurochem. 64 1995 895 901
57. A. Kabbara, N. Payet, D. Cottel, B. Frigard, P. Amouyel, and J.C. Lambert Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population Neurosci. Lett. 363 2004 139 143
58. S. Kalmijn, D. Foley, L. White, C.M. Burchfiel, J.D. Curb, H. Petrovitch, G.W. Ross, R.J. Havlik, and L.J. Launer Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study Arterioscler. Thromb. Vasc. Biol. 20 2000 2255 2260
59. M. Kawahara, and Y. Kuroda Intracellular calcium changes in neuronal cells induced by Alzheimer's beta-amyloid protein are blocked by estradiol and cholesterol Cell. Mol. Neurobiol. 21 2001 1 13
60. M. Kidd Paired helical filaments in electron microscopy of Alzheimer's disease Nature 197 1963 192 193
61. E.P. Kilsdonk, P.G. Yancey, G.W. Stoudt, F.W. Bangerter, W.J. Johnson, M.C. Phillips, and G.H. Rothblat Cellular cholesterol efflux mediated by cyclodextrins J. Biol. Chem. 270 1995 17250 17256
62. J.M. Kim, R. Stewart, I.S. Shin, and J.S. Yoon Low cholesterol, cognitive function and Alzheimer s disease in a community population with cognitive impairment J. Nutr. Health Aging 6 2002 320 323
63. M. Kivipelto, E.L. Helkala, M.P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, H. Soininen, J. Tuomilehto, and A. Nissinen Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study BMJ 322 2001 1447 1451
64. E. Kojro, G. Gimpl, S. Lammich, W. Marz, and F. Fahrenholz Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10 Proc. Natl. Acad. Sci. U.S.A. 98 2001 5815 5820
65. H. Kolsch, D. Lutjohann, M. Ludwig, A. Schulte, U. Ptok, F. Jessen, K. von Bergmann, M.L. Rao, W. Maier, and R. Heun Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease Mol. Psychiatry 7 2002 899 902
66. I.V. Kurochkin, and S. Goto Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme FEBS Lett. 345 1994 33 37
67. J. Kuusisto, K. Koivisto, L. Mykkanen, E.L. Helkala, M. Vanhanen, T. Hanninen, K. Kervinen, Y.A. Kesaniemi, P.J. Riekkinen, and M. Laakso Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study BMJ 315 1997 1045 1049
68. B.R. Kwak, N. Veillard, G. Pelli, F. Mulhaupt, R.W. James, M. Chanson, and F. Mach Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice Circulation 107 2003 1033 1039
69. U. Laufs, K. Gertz, P. Huang, G. Nickenig, M. Bohm, U. Dirnagl, and M. Endres Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice Stroke 31 2000 2442 2449
70. L.J. Launer, G.W. Ross, H. Petrovitch, K. Masaki, D. Foley, L.R. White, and R.J. Havlik Midlife blood pressure and dementia: the Honolulu-Asia aging study Neurobiol. Aging 21 2000 49 55
71. A. Lehtonen, and S. Luutonen High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia Age Ageing 15 1986 267 270
72. C.L. Leibson, W.A. Rocca, V.A. Hanson, R. Cha, E. Kokmen, P.C. O'Brien, and P.J. Palumbo Risk of dementia among persons with diabetes mellitus: a population-based cohort study Am. J. Epidemiol. 145 1997 301 308
73. H. Lennernas, and G. Fager Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. similarities and differences Clin. Pharmacokinet. 32 1997 403 425
74. G. Lesser, K. Kandiah, L.S. Libow, A. Likourezos, B. Breuer, D. Marin, R. Mohs, V. Haroutunian, and R. Neufeld Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease Dement. Geriatr. Cogn. Disord. 12 2001 138 145
75. Li, G., Higdon, R., Kukull, W.A., Peskind, E., Van Valen Moore, K., Tsuang, D., van Belle, G., McCormick, W., Bowen, J.D., Teri, L., Schellenberg, G.D., Larson, E.B., 2004. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 9; 63 (9),1624-1628.
76. S. Locatelli, D. Lutjohann, H.H. Schmidt, C. Otto, U. Beisiegel, and K. von Bergmann Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain Arch. Neurol. 59 2002 213 216
77. L. Lomnitski, R. Kohen, Y. Chen, E. Shohami, V. Trembovler, T. Vogel, and D.M. Michaelson Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury Pharmacol. Biochem. Behav. 56 1997 669 673
78. D. Lutjohann, A. Papassotiropoulos, I. Bjorkhem, S. Locatelli, M. Bagli, R.D. Oehring, U. Schlegel, F. Jessen, M.L. Rao, K. von Bergmann, and R. Heun Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients J. Lipid Res. 41 2000 195 198
79. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2000 207 213
80. M. Michikawa, Q.W. Fan, I. Isobe, and K. Yanagisawa Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture J. Neurochem. 74 2000 1008 1016
81. M.M. Mielke, P.P. Zandi, M. Sjögren, D. Gustafson, S. Östling, B. Steen, and I. Skoog Elevated total cholesterol levels in late-life associated with a reduced risk of dementia Neurology 64 2005 1689 1695
82. T.J. Muckle, and J.R. Roy High-density lipoprotein cholesterol in differential diagnosis of senile dementia Lancet 1 1985 1191 1193
83. H. Nawawi, N.S. Osman, K. Yusoff, and B.A. Khalid Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia Horm. Metab. Res. 35 2003 479 485
84. I.L. Notkola, R. Sulkava, J. Pekkanen, T. Erkinjuntti, C. Ehnholm, P. Kivinen, J. Tuomilehto, and A. Nissinen Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease Neuroepidemiology 17 1998 14 20
85. J.N. Octave The amyloid peptide precursor in Alzheimer's disease Acta Neurol. Belg. 95 1995 197 209
86. A. Ott, M.M. Breteler, M.C. de Bruyne, F. van Harskamp, D.E. Grobbee, and A. Hofman Atrial fibrillation and dementia in a population-based study. The Rotterdam Study Stroke 28 1997 316 321
87. A. Ott, R.P. Stolk, F. van Harskamp, H.A. Pols, A. Hofman, and M.M. Breteler Diabetes mellitus and the risk of dementia: the Rotterdam Study Neurology 53 1999 1937 1942
88. A. Papassotiropoulos, D. Lutjohann, M. Bagli, S. Locatelli, F. Jessen, R. Buschfort, U. Ptok, I. Bjorkhem, K. von Bergmann, and R. Heun 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia J. Psychiatr. Res. 36 2002 27 32
89. R. Peila, B.L. Rodriguez, and L.J. Launer Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study Diabetes 51 2002 1256 1262
90. H. Petrovitch, L.R. White, G. Izmirilian, G.W. Ross, R.J. Havlik, W. Markesbery, J. Nelson, D.G. Davis, J. Hardman, D.J. Foley, and L.J. Launer Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging study Neurobiol. Aging 21 2000 57 62
91. R.E. Pitas, J.K. Boyles, S.H. Lee, D. Hui, and K.H. Weisgraber Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain J. Biol. Chem. 262 1987 14352 14360
92. J. Poirier, and M. Panisset Apolipoprotein E: a novel therapeutic target for the treatment of Alzheimer's disease Adv. Behav. Biol. 1 2002 36 42
93. L. Puglielli, G. Konopka, E. Pack-Chung, L.A. Ingano, O. Berezovska, B.T. Hyman, T.Y. Chang, R.E. Tanzi, and D.M. Kovacs Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide Nat. Cell Biol. 3 2001 905 912
94. C. Qiu, B. Winblad, M. Viitanen, and L. Fratiglioni Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study Stroke 34 2003 594 599
95. M. Racchi, R. Baetta, N. Salvietti, P. Ianna, G. Franceschini, R. Paoletti, R. Fumagalli, S. Govoni, M. Trabucchi, and M. Soma Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content Biochem. J. 322 Pt 3 1997 893 898
96. L.M. Refolo, B. Malester, J. LaFrancois, T. Bryant-Thomas, R. Wang, G.S. Tint, K. Sambamurti, K. Duff, and M.A. Pappolla Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model Neurobiol. Dis. 7 2000 321 331
97. L.M. Refolo, M.A. Pappolla, J. LaFrancois, B. Malester, S.D. Schmidt, T. Thomas-Bryant, G.S. Tint, R. Wang, M. Mercken, S.S. Petanceska, and K.E. Duff A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease Neurobiol. Dis. 8 2001 890 899
98. E.M. Reiman, R.J. Caselli, K. Chen, G.E. Alexander, D. Bandy, and J. Frost Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 98 2001 3334 3339
99. C. Reitz, M.X. Tang, J. Luchsinger, and R. Mayeux Relation of plasma lipids to Alzheimer disease and vascular dementia Arch. Neurol. 61 2004 705 714
100. A. Rocchi, S. Pellegrini, G. Siciliano, and L. Murri Causative and susceptibility genes for Alzheimer's disease: a review Brain Res. Bull. 61 2003 1 24
101. K. Rockwood, S. Kirkland, D.B. Hogan, C. MacKnight, H. Merry, R. Verreault, C. Wolfson, and I. McDowell Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people Arch. Neurol. 59 2002 223 227
102. E.G. Rodriguez, H.H. Dodge, M.A. Birzescu, G.P. Stoehr, and M. Ganguli Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study J. Am. Geriatr. Soc. 50 2002 1852 1856
103. S.N. Romas, M.X. Tang, L. Berglund, and R. Mayeux APOE genotype, plasma lipids, lipoproteins, and AD in community elderly Neurology 53 1999 517 521
104. L.L. Rudel, R.G. Lee, and T.L. Cockman Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis Curr. Opin. Lipidol. 12 2001 121 127
105. H. Runz, J. Rietdorf, I. Tomic, M. de Bernard, K. Beyreuther, R. Pepperkok, and T. Hartmann Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells J. Neurosci. 22 2002 1679 1689
106. 4S-Study-Group, 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389.
107. S.L. Sabo, A.F. Ikin, J.D. Buxbaum, and P. Greengard The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement J. Cell Biol. 153 2001 1403 1414
108. R. Scacchi, L. De Bernardini, E. Mantuano, T. Vilardo, L.M. Donini, M. Ruggeri, A.T. Gemma, R. Pascone, and R.M. Corbo DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease Dement. Geriatr. Cogn. Disord. 9 1998 186 190
109. W.J. Schneider Familial hypercholesterolemia: dissection of a receptor disease Z. Kardiol. 79 Suppl. 3 1990 3 7
110. P. Schonknecht, D. Lutjohann, J. Pantel, H. Bardenheuer, T. Hartmann, K. von Bergmann, K. Beyreuther, and J. Schroder Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls Neurosci. Lett. 324 2002 83 85
111. H.D. Scott, and K. Laake Statins for the prevention of Alzheimer's disease Cochrane Database Syst. Rev. 2001 CD003160
112. Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M., Ford, I., Gaw, A., Hyland, M., Jukema, J.W., Kamper, A.M., Macfarlane, P.W., Meinders, A.E., Norrie, J., Packard, C.J., Perry, I.J., Stott, D.J., Sweeney, B.J., Twomey, C., Westendorp, R.G.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk, 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630.
113. G. Siest, P. Bertrand, B. Qin, B. Herbeth, J.M. Serot, L. Masana, J. Ribalta, A.P. Passmore, A. Evans, M. Ferrari, M. Franceschi, J. Shepherd, M. Cuchel, U. Beisiegel, K. Zuchowsky, A.S. Rukavina, J. Sertic, M. Stojanov, V. Kostic, A. Mitrevski, V. Petrova, C. Sass, A. Merched, J.T. Salonen, L. Tiret, and S. Visvikis Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope Group Clin. Chem. Lab. Med. 38 2000 721 730
114. K. Simons, and E. Ikonen How cells handle cholesterol Science 290 2000 1721 1726
115. M. Simons, P. Keller, B. De Strooper, K. Beyreuther, C.G. Dotti, and K. Simons Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons Proc. Natl. Acad. Sci. U.S.A. 95 1998 6460 6464
116. M. Simons, F. Schwarzler, D. Lutjohann, K. von Bergmann, K. Beyreuther, J. Dichgans, H. Wormstall, T. Hartmann, and J.B. Schulz Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial Ann. Neurol. 52 2002 346 350
117. C.F. Sing, and J. Davignon Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation Am. J. Hum. Genet. 37 1985 268 285
118. M. Sjögren, K. Gustafsson, S. Syversen, A. Olsson, Å. Edman, P. Davidsson, A. Wallin, and K. Blennow Treatment with simvastatin in patients with Alzheimer's disease lowers both α- and β-cleaved APP. Dementia Geriatr. Cogn. Disord. 16 2003 25 30
119. I. Skoog, B. Lernfelt, S. Landahl, B. Palmertz, L.A. Andreasson, L. Nilsson, G. Persson, A. Oden, and A. Svanborg 15-Year longitudinal study of blood pressure and dementia Lancet 347 1996 1141 1145
120. B.J. Small, A.B. Graves, C.L. McEvoy, F.C. Crawford, M. Mullan, and J.A. Mortimer Is APOE-epsilon4 a risk factor for cognitive impairment in normal aging? Neurology 54 2000 2082 2088
121. D.H. Small, V. Nurcombe, G. Reed, H. Clarris, R. Moir, K. Beyreuther, and C.L. Masters A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth J. Neurosci. 14 1994 2117 2127
122. G.E. Smith, D.L. Bohac, S.C. Waring, E. Kokmen, E.G. Tangalos, R.J. Ivnik, and R.C. Petersen Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects Neurology 50 1998 355 362
123. D.L. Sparks, J.C. Hunsaker 3rd, S.W. Scheff, R.J. Kryscio, J.L. Henson, and W.R. Markesbery Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease Neurobiol. Aging 11 1990 601 607
124. D.L. Sparks, H. Liu, S.W. Scheff, C.M. Coyne, and J.C. Hunsaker 3rd Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals J. Neuropathol. Exp. Neurol. 52 1993 135 142
125. D.L. Sparks, S.W. Scheff, J.C. Hunsaker 3rd, H. Liu, T. Landers, and D.R. Gross Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol Exp. Neurol. 126 1994 88 94
126. D.L. Sparks, S.W. Scheff, H. Liu, T.M. Landers, C.M. Coyne, and J.C. Hunsaker 3rd Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension J. Neurol. Sci. 131 1995 162 169
127. L. Sparks Benefit of atorvastatin in the treatment of Alzheimer's disease Montreal 2004
128. H.B. Staehelin, P. Perrig-Chiello, C. Mitrache, A.R. Miserez, and W.J. Perrig Apolipoprotein E genotypes and cognitive functions in healthy elderly persons Acta Neurol. Scand. 100 1999 53 60
129. J. Stamler, and R. Shekelle Dietary cholesterol and human coronary heart disease. The epidemiologic evidence Arch. Pathol. Lab. Med. 112 1988 1032 1040
130. W.J. Strittmatter, and A.D. Roses Apolipoprotein E and Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 92 1995 4725 4727
131. N. Suzuki, T. Iwatsubo, A. Odaka, Y. Ishibashi, C. Kitada, and Y. Ihara High tissue content of soluble beta1-40 is linked to cerebral amyloid angiopathy Am. J. Pathol. 145 1994 452 460
132. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors Arterioscler. Thromb. Vasc. Biol. 21 2001 1712 1719
133. Z.S. Tan, S. Seshadri, A. Beiser, P.W. Wilson, D.P. Kiel, M. Tocco, R.B. D'Agostino, and P.A. Wolf Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study Arch. Intern. Med. 163 2003 1053 1057
134. K. Tanaka, M. Honda, and T. Takabatake Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation Clin. Exp. Pharmacol. Physiol. 31 2004 360 364
135. Tomlinson, B., Henderson, G., 1976. Some quantitative cerebral findings in normal and demented old people. Neurobiology of Aging. G.S. Terry RD. Raven Press, New York.
136. B.E. Tomlinson, and J.A.N. Corsellis Ageing and the dementias J. Hume Adams J.A.N. Corsellis L.W. Duchen Greenfield's Neuropathology 1984 Edward Arnold London 951 1025
137. F.A. Tremollieres, J.M. Pouilles, C. Cauneille, and C. Ribot Coronary heart disease risk factors and menopause: a study in 1684 French women Atherosclerosis 142 1999 415 423
138. H. Tun, L. Marlow, I. Pinnix, R. Kinsey, and K. Sambamurti Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway J. Mol. Neurosci. 19 2002 31 35
139. C.J. Vaughan, M.B. Murphy, and B.M. Buckley Statins do more than just lower cholesterol Lancet 348 1996 1079 1082
140. S. Wassmann, U. Laufs, K. Muller, C. Konkol, K. Ahlbory, A.T. Baumer, W. Linz, M. Bohm, and G. Nickenig Cellular antioxidant effects of atorvastatin in vitro and in vivo Arterioscler. Thromb. Vasc. Biol. 22 2002 300 305
141. J.K. Williams, G.K. Sukhova, D.M. Herrington, and P. Libby Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys J. Am. Coll. Cardiol. 31 1998 684 691
142. C.M. Wischik, M. Novak, H.C. Thogersen, P.C. Edwards, M.J. Runswick, R. Jakes, J.E. Walker, C. Milstein, M. Roth, and A. Klug Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 85 1988 4506 4510
143. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, and G. Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors Arch. Neurol. 57 10 2000 1439 1443
144. B. Wolozin Cholesterol, statins and dementia Curr. Opin. Lipidol. 15 2004 667 672
145. C.W. Wu, P.C. Liao, C. Lin, C.J. Kuo, S.T. Chen, H.I. Chen, and Y.M. Kuo Brain region-dependent increases in beta-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits J. Neural. Transm. 110 2003 641 649
146. K. Yaffe, E. Barrett-Connor, F. Lin, and D. Grady Serum lipoprotein levels, statin use, and cognitive function in older women Arch. Neurol. 59 2002 378 384
147. T. Yoshitake, Y. Kiyohara, I. Kato, T. Ohmura, H. Iwamoto, K. Nakayama, S. Ohmori, K. Nomiyama, H. Kawano, and K. Ueda Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study Neurology 45 1995 1161 1168
148. Zandi, P.P., Sparks, D.L., Khachaturian, A.S., Tschanz, J., Norton, M., Steinberg, M., Welsh-Bohmer, K.A., Breitner, J.C.; Cache County Study investigators, 2005. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry. 62 (2), 217-224.